<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:52:58 -0700</creation_date>
  <update_date>2013-05-27 11:08:26 -0600</update_date>
  <accession>HMDBP01038</accession>
  <secondary_accessions>
    <accession>6326</accession>
    <accession>HMDBP04437</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>(R)-limonene 6-monooxygenase</synonym>
    <synonym>(S)-limonene 6-monooxygenase</synonym>
    <synonym>(S)-limonene 7-monooxygenase</synonym>
    <synonym>CYPIIC17</synonym>
    <synonym>CYPIIC19</synonym>
    <synonym>Cytochrome P450-11A</synonym>
    <synonym>Cytochrome P450-254C</synonym>
    <synonym>Mephenytoin 4-hydroxylase</synonym>
  </synonyms>
  <gene_name>CYP2C19</gene_name>
  <general_function>Involved in monooxygenase activity</general_function>
  <specific_function>Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
</specific_function>
  <pathways>
    <pathway>
      <name>Arachidonic acid metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00590</kegg_map_id>
    </pathway>
    <pathway>
      <name>Linoleic acid metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00591</kegg_map_id>
    </pathway>
    <pathway>
      <name>Retinol metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00830</kegg_map_id>
    </pathway>
    <pathway>
      <name>Metabolism of xenobiotics by cytochrome P450</name>
      <smpdb_id/>
      <kegg_map_id>map00980</kegg_map_id>
    </pathway>
    <pathway>
      <name>Drug metabolism - cytochrome P450</name>
      <smpdb_id/>
      <kegg_map_id>map00982</kegg_map_id>
    </pathway>
    <pathway>
      <name>Serotonergic synapse</name>
      <smpdb_id/>
      <kegg_map_id>map04726</kegg_map_id>
    </pathway>
    <pathway>
      <name>Chemical carcinogenesis</name>
      <smpdb_id/>
      <kegg_map_id>map05204</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB01043</accession>
      <name>Arachidonic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04244</accession>
      <name>15(S)-HPETE</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04680</accession>
      <name>16(R)-HETE</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04264</accession>
      <name>14,15-Epoxy-5,8,11-eicosatrienoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04673</accession>
      <name>11,12-Epoxyeicosatrienoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02232</accession>
      <name>8,9-Epoxyeicosatrienoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02190</accession>
      <name>5,6-Epoxy-8,11,14-eicosatrienoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04693</accession>
      <name>11H-14,15-EETA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05050</accession>
      <name>15H-11,12-EETA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04694</accession>
      <name>11,14,15-THETA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04684</accession>
      <name>11,12,15-THETA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03178</accession>
      <name>Heme</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00217</accession>
      <name>NADP</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00221</accession>
      <name>NADPH</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01984</accession>
      <name>Finasteride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01913</accession>
      <name>Omeprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05008</accession>
      <name>Lansoprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05000</accession>
      <name>Loratadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05038</accession>
      <name>Citalopram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01919</accession>
      <name>Famotidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01848</accession>
      <name>Imipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01930</accession>
      <name>Ranitidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05026</accession>
      <name>Rabeprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05034</accession>
      <name>Topiramate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05010</accession>
      <name>Sertraline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05017</accession>
      <name>Pantoprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03634</accession>
      <name>Perillyl alcohol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00053</accession>
      <name>Androstenedione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00142</accession>
      <name>Formic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00145</accession>
      <name>Estrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00151</accession>
      <name>Estradiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00234</accession>
      <name>Testosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00673</accession>
      <name>Linoleic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01355</accession>
      <name>Parathion</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01377</accession>
      <name>Oxygen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01426</accession>
      <name>Formaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01847</accession>
      <name>Caffeine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01852</accession>
      <name>All-trans-retinoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01860</accession>
      <name>Paraxanthine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01877</accession>
      <name>Valproic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02833</accession>
      <name>Testosterone sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03276</accession>
      <name>Hydrogen sulfide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03375</accession>
      <name>D-Limonene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03450</accession>
      <name>(-)-trans-Carveol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03955</accession>
      <name>19-Hydroxyandrost-4-ene-3,17-dione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03956</accession>
      <name>7a-Hydroxytestosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03959</accession>
      <name>19-Oxotestosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04081</accession>
      <name>6-Hydroxymelatonin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04321</accession>
      <name>(+)-Limonene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04701</accession>
      <name>9,10-Epoxyoctadecenoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04702</accession>
      <name>12,13-EpOME</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04995</accession>
      <name>Codeine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06768</accession>
      <name>19-Oxoandrost-4-ene-3,17-dione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06769</accession>
      <name>19-Hydroxytestosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11136</accession>
      <name>19(S)-HETE</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01830</accession>
      <name>Progesterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12242</accession>
      <name>Ketoconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01389</accession>
      <name>Melatonin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00876</accession>
      <name>Vitamin D3</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14322</accession>
      <name>Fluvoxamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01934</accession>
      <name>L(-)-Nicotine pestanal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14334</accession>
      <name>Bortezomib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14342</accession>
      <name>Fluconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13921</accession>
      <name>7-Hydroxyticlopidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14359</accession>
      <name>Torasemide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14021</accession>
      <name>N-Desmethylcitalopram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13919</accession>
      <name>N-Desmethyleletriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14365</accession>
      <name>Nelfinavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14369</accession>
      <name>Indinavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14372</accession>
      <name>Lovastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14376</accession>
      <name>Temazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14384</accession>
      <name>Oxiconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14390</accession>
      <name>Benzatropine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13851</accession>
      <name>N-Acetyldapsone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13895</accession>
      <name>3',4'-Dihydrodiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14404</accession>
      <name>Sulfanilamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14434</accession>
      <name>Atomoxetine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14442</accession>
      <name>Bupivacaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14457</accession>
      <name>Pentobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13897</accession>
      <name>4-ene-Valproic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14477</accession>
      <name>Methadone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14010</accession>
      <name>5-Hydroxyomeprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14487</accession>
      <name>Diltiazem</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14491</accession>
      <name>Trimethadione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14493</accession>
      <name>Clobazam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14501</accession>
      <name>Aminoglutethimide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14515</accession>
      <name>Meprobamate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14517</accession>
      <name>Timolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14539</accession>
      <name>Carisoprodol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14542</accession>
      <name>Sorafenib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13938</accession>
      <name>Promazine 5-sulfoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14587</accession>
      <name>Teniposide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14589</accession>
      <name>Chloramphenicol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14008</accession>
      <name>Hydroxylansoprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14597</accession>
      <name>Meperidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14611</accession>
      <name>Quinine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14613</accession>
      <name>Dronabinol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14638</accession>
      <name>Zidovudine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14642</accession>
      <name>Flutamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14644</accession>
      <name>Cimetidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14645</accession>
      <name>Haloperidol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14646</accession>
      <name>Ritonavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13856</accession>
      <name>4-Hydroxycyclophosphamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14680</accession>
      <name>Nortriptyline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14686</accession>
      <name>Adinazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14689</accession>
      <name>Zafirlukast</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14704</accession>
      <name>Carbamazepine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14720</accession>
      <name>Voriconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13974</accession>
      <name>4'-Hydroxydiclofenac</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14728</accession>
      <name>Doxazosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14742</accession>
      <name>Cisapride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13862</accession>
      <name>N-desmethylimatinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14760</accession>
      <name>Nicardipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14763</accession>
      <name>Efavirenz</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14773</accession>
      <name>Prednisone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13961</accession>
      <name>O-Desmethylverapamil (D-702)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14803</accession>
      <name>Nilutamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14024</accession>
      <name>2-Hydroxychlorpropamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14811</accession>
      <name>Aprepitant</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13866</accession>
      <name>N-Desmethyltamoxifen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13846</accession>
      <name>E-3179</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14817</accession>
      <name>Thioridazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13880</accession>
      <name>S-6-Hydroxywarfarin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14839</accession>
      <name>Amprenavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14841</accession>
      <name>Methazolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14843</accession>
      <name>Delavirdine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14855</accession>
      <name>Norethindrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14864</accession>
      <name>Trimipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14874</accession>
      <name>Esomeprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14876</accession>
      <name>Pentamidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14883</accession>
      <name>Modafinil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14886</accession>
      <name>Carbinoxamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14890</accession>
      <name>Tranylcypromine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14892</accession>
      <name>Ethotoin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13929</accession>
      <name>2-Oxoclopidogrel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14901</accession>
      <name>Methimazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14914</accession>
      <name>Oxcarbazepine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14918</accession>
      <name>Phenelzine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14932</accession>
      <name>Primidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14018</accession>
      <name>4-Hydroxypropofol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14970</accession>
      <name>Phensuximide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14987</accession>
      <name>Methylphenobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14988</accession>
      <name>Perphenazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14995</accession>
      <name>Terbinafine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00108</accession>
      <name>Ethanol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15045</accession>
      <name>Zonisamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15054</accession>
      <name>Almotriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15067</accession>
      <name>Tipranavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01879</accession>
      <name>Aspirin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15084</accession>
      <name>Felbamate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15086</accession>
      <name>Isoniazid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15101</accession>
      <name>Telmisartan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15102</accession>
      <name>Desloratadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15115</accession>
      <name>Ramelteon</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15118</accession>
      <name>Formoterol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00073</accession>
      <name>Dopamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15142</accession>
      <name>Tioconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15151</accession>
      <name>Glyburide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15153</accession>
      <name>Guanfacine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15166</accession>
      <name>Probenecid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13972</accession>
      <name>N-Dealkylated tolterodine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15171</accession>
      <name>Selegiline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13870</accession>
      <name>cis,trans-5'-Hydroxythalidomide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15177</accession>
      <name>Memantine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15179</accession>
      <name>Rifampin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15191</accession>
      <name>Praziquantel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15193</accession>
      <name>Amoxicillin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02151</accession>
      <name>Dimethyl sulfoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14037</accession>
      <name>6-Hydroxyfluvastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15230</accession>
      <name>Rosuvastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15232</accession>
      <name>Pimozide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15242</accession>
      <name>Miconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14027</accession>
      <name>7-Hydroxygliclazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15256</accession>
      <name>Tolbutamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15260</accession>
      <name>Bicalutamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15263</accession>
      <name>Proguanil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15264</accession>
      <name>Pioglitazone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15273</accession>
      <name>Doxepin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15282</accession>
      <name>Desipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15297</accession>
      <name>Cilostazol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15302</accession>
      <name>Moclobemide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15310</accession>
      <name>Podofilox</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13858</accession>
      <name>3-Dechloroethylifosfamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15322</accession>
      <name>Dexfenfluramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15342</accession>
      <name>Clarithromycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15362</accession>
      <name>Saquinavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15364</accession>
      <name>Dexamethasone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15371</accession>
      <name>Gemfibrozil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15372</accession>
      <name>Clomipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15388</accession>
      <name>Lapatinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15399</accession>
      <name>Arformoterol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15403</accession>
      <name>Lumiracoxib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15417</accession>
      <name>Fosphenytoin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13940</accession>
      <name>3'-Hydroxyhexobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15448</accession>
      <name>Troleandomycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15487</accession>
      <name>Acenocoumarol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13839</accession>
      <name>N-Desmethylaminopyrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13840</accession>
      <name>3-Hydroxymethylantipyrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15510</accession>
      <name>Flunitrazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15511</accession>
      <name>Bromazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15512</accession>
      <name>Clotiazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15528</accession>
      <name>Quazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15539</accession>
      <name>Lopinavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15558</accession>
      <name>Pipotiazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13997</accession>
      <name>6-Hydroxymethyletoricoxib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15583</accession>
      <name>Bifonazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15609</accession>
      <name>Trabectedin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15611</accession>
      <name>Methsuximide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15629</accession>
      <name>Sitaxentan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15643</accession>
      <name>Artemether</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15657</accession>
      <name>Nilvadipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15661</accession>
      <name>Fospropofol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15662</accession>
      <name>Fosaprepitant</name>
    </metabolite>
    <metabolite>
      <accession>HMDB59608</accession>
      <name>(+)-trans-Carveol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB36088</accession>
      <name>(S)-p-Mentha-1,8-dien-7-ol</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>heme binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>electron carrier activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transition metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>iron ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>monooxygenase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxidation reduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>endoplasmic reticulum membrane</description>
      <go_id>GO:0005789</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>(R)-limonene 6-monooxygenase activity</description>
      <go_id>GO:0052741</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>(S)-limonene 6-monooxygenase activity</description>
      <go_id>GO:0018675</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>(S)-limonene 7-monooxygenase activity</description>
      <go_id>GO:0018676</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>electron carrier activity</description>
      <go_id>GO:0009055</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>heme binding</description>
      <go_id>GO:0020037</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>iron ion binding</description>
      <go_id>GO:0005506</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>oxygen binding</description>
      <go_id>GO:0019825</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>steroid hydroxylase activity</description>
      <go_id>GO:0008395</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>exogenous drug catabolic process</description>
      <go_id>GO:0042738</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>heterocycle metabolic process</description>
      <go_id>GO:0046483</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>monoterpenoid metabolic process</description>
      <go_id>GO:0016098</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>small molecule metabolic process</description>
      <go_id>GO:0044281</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>steroid metabolic process</description>
      <go_id>GO:0008202</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>xenobiotic metabolic process</description>
      <go_id>GO:0006805</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Endoplasmic reticulum membrane</subcellular_location>
    <subcellular_location>Peripheral membrane protein</subcellular_location>
    <subcellular_location>Microsome membrane</subcellular_location>
    <subcellular_location>Peripheral membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>10</chromosome_location>
    <locus>10q24</locus>
    <gene_sequence>&gt;1473 bp
ATGGATCCTTTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCAATCTGG
AGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA
AATATCCTACAGATAGATATTAAGGATGTCAGCAAATCCTTAACCAATCTCTCAAAAATC
TATGGCCCTGTGTTCACTCTGTATTTTGGCCTGGAACGCATGGTGGTGCTGCATGGATAT
GAAGTGGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCCATTTC
CCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATCGTTTTCAGCAATGGAAAGAGATGG
AAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
ATTATTTTCCAGAAACGTTTCGATTATAAAGATCAGCAATTTCTTAACTTGATGGAAAAA
TTGAATGAAAACATCAGGATTGTAAGCACCCCCTGGATCCAGATATGCAATAATTTTCCC
ACTATCATTGATTATTTCCCGGGAACCCATAACAAATTACTTAAAAACCTTGCTTTTATG
GAAAGTGATATTTTGGAGAAAGTAAAAGAACACCAAGAATCGATGGACATCAACAACCCT
CGGGACTTTATTGATTGCTTCCTGATCAAAATGGAGAAGGAAAAGCAAAACCAACAGTCT
GAATTCACTATTGAAAACTTGGTAATCACTGCAGCTGACTTACTTGGAGCTGGGACAGAG
ACAACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGAACGTGTCATTGGCAGAAACCGGAGCCCCTGCATGCAG
GACAGGGGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATCGAC
CTCATCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACGTTAAATTCAGAAACTACCTC
ATTCCCAAGGGCACAACCATATTAACTTCCCTCACTTCTGTGCTACATGACAACAAAGAA
TTTCCCAACCCAGAGATGTTTGACCCTCGTCACTTTCTGGATGAAGGTGGAAATTTTAAG
AAAAGTAACTACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAGGGCCTG
GCCCGCATGGAGCTGTTTTTATTCCTGACCTTCATTTTACAGAACTTTAACCTGAAATCT
CTGATTGACCCAAAGGACCTTGACACAACTCCTGTTGTCAATGGATTTGCTTCTGTCCCG
CCCTTCTATCAGCTGTGCTTCATTCCTGTCTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>490</residue_number>
    <molecular_weight>55944.565</molecular_weight>
    <theoretical_pi>7.383</theoretical_pi>
    <pfams>
      <pfam>
        <name>p450</name>
        <pfam_id>PF00067</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV</protein_sequence>
  </protein_properties>
  <genbank_protein_id>181344</genbank_protein_id>
  <uniprot_id>P33261</uniprot_id>
  <uniprot_name>CP2CJ_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>4GQS</pdb_id>
  </pdb_ids>
  <genbank_gene_id>M61854</genbank_gene_id>
  <genecard_id>CYP2C19</genecard_id>
  <geneatlas_id>CYP2C19</geneatlas_id>
  <hgnc_id>HGNC:2621</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA: Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry. 1991 Apr 2;30(13):3247-55.</reference_text>
      <pubmed_id>2009263</pubmed_id>
    </reference>
    <reference>
      <reference_text>Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA: Cloning and expression of complementary DNAs for multiple members of the human cytochrome PH50IIC subfamily. Biochemistry. 1993 Feb 9;32(5):1390.</reference_text>
      <pubmed_id>8095407</pubmed_id>
    </reference>
    <reference>
      <reference_text>Deloukas P, Earthrowl ME, Grafham DV, Rubenfield M, French L, Steward CA, Sims SK, Jones MC, Searle S, Scott C, Howe K, Hunt SE, Andrews TD, Gilbert JG, Swarbreck D, Ashurst JL, Taylor A, Battles J, Bird CP, Ainscough R, Almeida JP, Ashwell RI, Ambrose KD, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Bates K, Beasley H, Bray-Allen S, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Cahill P, Camire D, Carter NP, Chapman JC, Clark SY, Clarke G, Clee CM, Clegg S, Corby N, Coulson A, Dhami P, Dutta I, Dunn M, Faulkner L, Frankish A, Frankland JA, Garner P, Garnett J, Gribble S, Griffiths C, Grocock R, Gustafson E, Hammond S, Harley JL, Hart E, Heath PD, Ho TP, Hopkins B, Horne J, Howden PJ, Huckle E, Hynds C, Johnson C, Johnson D, Kana A, Kay M, Kimberley AM, Kershaw JK, Kokkinaki M, Laird GK, Lawlor S, Lee HM, Leongamornlert DA, Laird G, Lloyd C, Lloyd DM, Loveland J, Lovell J, McLaren S, McLay KE, McMurray A, Mashreghi-Mohammadi M, Matthews L, Milne S, Nickerson T, Nguyen M, Overton-Larty E, Palmer SA, Pearce AV, Peck AI, Pelan S, Phillimore B, Porter K, Rice CM, Rogosin A, Ross MT, Sarafidou T, Sehra HK, Shownkeen R, Skuce CD, Smith M, Standring L, Sycamore N, Tester J, Thorpe A, Torcasso W, Tracey A, Tromans A, Tsolas J, Wall M, Walsh J, Wang H, Weinstock K, West AP, Willey DL, Whitehead SL, Wilming L, Wray PW, Young L, Chen Y, Lovering RC, Moschonas NK, Siebert R, Fechtel K, Bentley D, Durbin R, Hubbard T, Doucette-Stamm L, Beck S, Smith DR, Rogers J: The DNA sequence and comparative analysis of human chromosome 10.  Nature. 2004 May 27;429(6990):375-81.</reference_text>
      <pubmed_id>15164054</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wrighton SA, Stevens JC, Becker GW, VandenBranden M: Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys. 1993 Oct;306(1):240-5.</reference_text>
      <pubmed_id>8215410</pubmed_id>
    </reference>
    <reference>
      <reference_text>Miyazawa M, Shindo M, Shimada T: Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes. Drug Metab Dispos. 2002 May;30(5):602-7.</reference_text>
      <pubmed_id>11950794</pubmed_id>
    </reference>
    <reference>
      <reference_text>de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994 Jun 3;269(22):15419-22.</reference_text>
      <pubmed_id>8195181</pubmed_id>
    </reference>
    <reference>
      <reference_text>De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994 Oct;46(4):594-8.</reference_text>
      <pubmed_id>7969038</pubmed_id>
    </reference>
    <reference>
      <reference_text>Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, Xu ZH, Zhou HH: Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther. 1997 Apr;281(1):604-9.</reference_text>
      <pubmed_id>9103550</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, Ghanayem BI, Blaisdell J: Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther. 1998 Sep;286(3):1490-5.</reference_text>
      <pubmed_id>9732415</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Daly AK, Goldstein JA: An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics. 1998 Apr;8(2):129-35.</reference_text>
      <pubmed_id>10022751</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA: A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther. 1999 Aug;290(2):635-40.</reference_text>
      <pubmed_id>10411572</pubmed_id>
    </reference>
    <reference>
      <reference_text>Blaisdell J, Mohrenweiser H, Jackson J, Ferguson S, Coulter S, Chanas B, Xi T, Ghanayem B, Goldstein JA: Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics. 2002 Dec;12(9):703-11.</reference_text>
      <pubmed_id>12464799</pubmed_id>
    </reference>
    <reference>
      <reference_text>Morita J, Kobayashi K, Wanibuchi A, Kimura M, Irie S, Ishizaki T, Chiba K: A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4'-hydroxylation. Drug Metab Pharmacokinet. 2004 Jun;19(3):236-8.</reference_text>
      <pubmed_id>15499191</pubmed_id>
    </reference>
    <reference>
      <reference_text>Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP: Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics. 2004 Oct;5(7):895-931.</reference_text>
      <pubmed_id>15469410</pubmed_id>
    </reference>
    <reference>
      <reference_text>Fukushima-Uesaka H, Saito Y, Maekawa K, Ozawa S, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Tohkin M, Sawada J: Genetic variations and haplotypes of CYP2C19 in a Japanese population.  Drug Metab Pharmacokinet. 2005 Aug;20(4):300-7.</reference_text>
      <pubmed_id>16141610</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Estradiol</name>
        <accession>HMDB00151</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Testosterone</name>
        <accession>HMDB00234</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M: Substrate inhibition kinetics for cytochrome P450-catalyzed reactions.  Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74.</reference_text>
        <pubmed_id>11259318</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Melatonin</name>
        <accession>HMDB01389</accession>
      </metabolite>
      <reference>
        <reference_text>Huuhka K, Riutta A, Haataja R, Ylitalo P, Leinonen E: The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: A randomized, double-blind, placebo-controlled study. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):447-50.</reference_text>
        <pubmed_id>17003850</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Melatonin</name>
        <accession>HMDB01389</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vitamin D3</name>
        <accession>HMDB00876</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69.</reference_text>
        <pubmed_id>8968657</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L(-)-Nicotine pestanal</name>
        <accession>HMDB01934</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bortezomib</name>
        <accession>HMDB14334</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bortezomib</name>
        <accession>HMDB14334</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluconazole</name>
        <accession>HMDB14342</accession>
      </metabolite>
      <reference>
        <reference_text>Niwa T, Shiraga T, Takagi A: Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005 Sep;28(9):1805-8.</reference_text>
        <pubmed_id>16141567</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluconazole</name>
        <accession>HMDB14342</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>7-Hydroxyticlopidine</name>
        <accession>HMDB13921</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>7-Hydroxyticlopidine</name>
        <accession>HMDB13921</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Torasemide</name>
        <accession>HMDB14359</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Brosen K, Naranjo CA: Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001 Aug;11(4):275-83.</reference_text>
        <pubmed_id>11532381</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54.</reference_text>
        <pubmed_id>10774624</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes.  Xenobiotica. 1998 Dec;28(12):1203-53.</reference_text>
        <pubmed_id>9890159</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyleletriptan</name>
        <accession>HMDB13919</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nelfinavir</name>
        <accession>HMDB14365</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nelfinavir</name>
        <accession>HMDB14365</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indinavir</name>
        <accession>HMDB14369</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.</reference_text>
        <pubmed_id>11523064</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Temazepam</name>
        <accession>HMDB14376</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxiconazole</name>
        <accession>HMDB14384</accession>
      </metabolite>
      <reference>
        <reference_text>Mahajan MK, Uttamsingh V, Daniels JS, Gan LS, LeDuc BW, Williams DA: In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. Drug Metab Dispos. 2011 Apr;39(4):693-702. Epub 2010 Dec 21.</reference_text>
        <pubmed_id>21177487</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzatropine</name>
        <accession>HMDB14390</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Acetyldapsone</name>
        <accession>HMDB13851</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Acetyldapsone</name>
        <accession>HMDB13851</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3',4'-Dihydrodiol</name>
        <accession>HMDB13895</accession>
      </metabolite>
      <reference>
        <reference_text>Levy RH: Cytochrome P450 isozymes and antiepileptic drug interactions.  Epilepsia. 1995;36 Suppl 5:S8-13.</reference_text>
        <pubmed_id>8806399</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3',4'-Dihydrodiol</name>
        <accession>HMDB13895</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3',4'-Dihydrodiol</name>
        <accession>HMDB13895</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3',4'-Dihydrodiol</name>
        <accession>HMDB13895</accession>
      </metabolite>
      <reference>
        <reference_text>Komatsu T, Yamazaki H, Asahi S, Gillam EM, Guengerich FP, Nakajima M, Yokoi T: Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. Drug Metab Dispos. 2000 Nov;28(11):1361-8.</reference_text>
        <pubmed_id>11038165</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3',4'-Dihydrodiol</name>
        <accession>HMDB13895</accession>
      </metabolite>
      <reference>
        <reference_text>Kaminsky LS, Zhang ZY: Human P450 metabolism of warfarin.  Pharmacol Ther. 1997;73(1):67-74.</reference_text>
        <pubmed_id>9014207</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfanilamide</name>
        <accession>HMDB14404</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atomoxetine</name>
        <accession>HMDB14434</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bupivacaine</name>
        <accession>HMDB14442</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentobarbital</name>
        <accession>HMDB14457</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-ene-Valproic acid</name>
        <accession>HMDB13897</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadone</name>
        <accession>HMDB14477</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadone</name>
        <accession>HMDB14477</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Foti RS, Wahlstrom JL: CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos. 2008 Mar;36(3):523-8. Epub 2007 Nov 29.</reference_text>
        <pubmed_id>18048485</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7.</reference_text>
        <pubmed_id>15258107</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Li XQ, Weidolf L, Simonsson R, Andersson TB: Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J Pharmacol Exp Ther. 2005 Nov;315(2):777-87. Epub 2005 Aug 10.</reference_text>
        <pubmed_id>16093273</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T: Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 1997 Nov;283(2):434-42.</reference_text>
        <pubmed_id>9353355</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diltiazem</name>
        <accession>HMDB14487</accession>
      </metabolite>
      <reference>
        <reference_text>Kosuge K, Jun Y, Watanabe H, Kimura M, Nishimoto M, Ishizaki T, Ohashi K: Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab Dispos. 2001 Oct;29(10):1284-9.</reference_text>
        <pubmed_id>11560871</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diltiazem</name>
        <accession>HMDB14487</accession>
      </metabolite>
      <reference>
        <reference_text>McGinnity DF, Parker AJ, Soars M, Riley RJ: Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metab Dispos. 2000 Nov;28(11):1327-34.</reference_text>
        <pubmed_id>11038161</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethadione</name>
        <accession>HMDB14491</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethadione</name>
        <accession>HMDB14491</accession>
      </metabolite>
      <reference>
        <reference_text>Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7.</reference_text>
        <pubmed_id>9879636</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clobazam</name>
        <accession>HMDB14493</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminoglutethimide</name>
        <accession>HMDB14501</accession>
      </metabolite>
      <reference>
        <reference_text>Santen RJ, Misbin RI: Aminoglutethimide: review of pharmacology and clinical use.  Pharmacotherapy. 1981 Sep-Oct;1(2):95-120.</reference_text>
        <pubmed_id>6765487</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meprobamate</name>
        <accession>HMDB14515</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Timolol</name>
        <accession>HMDB14517</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carisoprodol</name>
        <accession>HMDB14539</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sorafenib</name>
        <accession>HMDB14542</accession>
      </metabolite>
      <reference>
        <reference_text>Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. Epub 2011 Feb 25.</reference_text>
        <pubmed_id>21350850</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promazine 5-sulfoxide</name>
        <accession>HMDB13938</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promazine 5-sulfoxide</name>
        <accession>HMDB13938</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloramphenicol</name>
        <accession>HMDB14589</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxylansoprazole</name>
        <accession>HMDB14008</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxylansoprazole</name>
        <accession>HMDB14008</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meperidine</name>
        <accession>HMDB14597</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meperidine</name>
        <accession>HMDB14597</accession>
      </metabolite>
      <reference>
        <reference_text>Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ: CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6.</reference_text>
        <pubmed_id>15319333</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinine</name>
        <accession>HMDB14611</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dronabinol</name>
        <accession>HMDB14613</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dronabinol</name>
        <accession>HMDB14613</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zidovudine</name>
        <accession>HMDB14638</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flutamide</name>
        <accession>HMDB14642</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cimetidine</name>
        <accession>HMDB14644</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Haloperidol</name>
        <accession>HMDB14645</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ritonavir</name>
        <accession>HMDB14646</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-Hydroxycyclophosphamide</name>
        <accession>HMDB13856</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Olesen OV, Linnet K: Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997 Jun;25(6):740-4.</reference_text>
        <pubmed_id>9193876</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adinazolam</name>
        <accession>HMDB14686</accession>
      </metabolite>
      <reference>
        <reference_text>Venkatakrishnan K, von Moltke LL, Duan SX, Fleishaker JC, Shader RI, Greenblatt DJ: Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 1998 Mar;50(3):265-74.</reference_text>
        <pubmed_id>9600717</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adinazolam</name>
        <accession>HMDB14686</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zafirlukast</name>
        <accession>HMDB14689</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbamazepine</name>
        <accession>HMDB14704</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Voriconazole</name>
        <accession>HMDB14720</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Voriconazole</name>
        <accession>HMDB14720</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4'-Hydroxydiclofenac</name>
        <accession>HMDB13974</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cisapride</name>
        <accession>HMDB14742</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nicardipine</name>
        <accession>HMDB14760</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Efavirenz</name>
        <accession>HMDB14763</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prednisone</name>
        <accession>HMDB14773</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nilutamide</name>
        <accession>HMDB14803</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>2-Hydroxychlorpropamide</name>
        <accession>HMDB14024</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>2-Hydroxychlorpropamide</name>
        <accession>HMDB14024</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aprepitant</name>
        <accession>HMDB14811</accession>
      </metabolite>
      <reference>
        <reference_text>Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu SH, Evans DC, Huskey SE: Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 Nov;32(11):1287-92. Epub 2004 Aug 10.</reference_text>
        <pubmed_id>15304427</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aprepitant</name>
        <accession>HMDB14811</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Desta Z, Ward BA, Soukhova NV, Flockhart DA: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75. Epub 2004 May 24.</reference_text>
        <pubmed_id>15159443</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM: Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.</reference_text>
        <pubmed_id>12124303</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>E-3179</name>
        <accession>HMDB13846</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Thioridazine</name>
        <accession>HMDB14817</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>S-6-Hydroxywarfarin</name>
        <accession>HMDB13880</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>S-6-Hydroxywarfarin</name>
        <accession>HMDB13880</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amprenavir</name>
        <accession>HMDB14839</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methazolamide</name>
        <accession>HMDB14841</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Delavirdine</name>
        <accession>HMDB14843</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norethindrone</name>
        <accession>HMDB14855</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimipramine</name>
        <accession>HMDB14864</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Esomeprazole</name>
        <accession>HMDB14874</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Esomeprazole</name>
        <accession>HMDB14874</accession>
      </metabolite>
      <reference>
        <reference_text>Klotz U: Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther. 2006 Jul;44(7):297-302.</reference_text>
        <pubmed_id>16961157</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentamidine</name>
        <accession>HMDB14876</accession>
      </metabolite>
      <reference>
        <reference_text>Afrin LB, Afrin JB: Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Clin Transplant. 2011 May-Jun;25(3):E271-5. doi:       10.1111/j.1399-0012.2011.01399.x. Epub 2011 Feb 7.</reference_text>
        <pubmed_id>21299635</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Modafinil</name>
        <accession>HMDB14883</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbinoxamine</name>
        <accession>HMDB14886</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Stadel R, Yang J, Nalwalk JW, Phillips JG, Hough LB: High-affinity binding of [3H]cimetidine to a heme-containing protein in rat brain. Drug Metab Dispos. 2008 Mar;36(3):614-21. Epub 2007 Dec 19.</reference_text>
        <pubmed_id>18094038</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Salsali M, Holt A, Baker GB: Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol. 2004 Feb;24(1):63-76.</reference_text>
        <pubmed_id>15049511</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethotoin</name>
        <accession>HMDB14892</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>2-Oxoclopidogrel</name>
        <accession>HMDB13929</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>2-Oxoclopidogrel</name>
        <accession>HMDB13929</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methimazole</name>
        <accession>HMDB14901</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxcarbazepine</name>
        <accession>HMDB14914</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Primidone</name>
        <accession>HMDB14932</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-Hydroxypropofol</name>
        <accession>HMDB14018</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phensuximide</name>
        <accession>HMDB14970</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenobarbital</name>
        <accession>HMDB14987</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Perphenazine</name>
        <accession>HMDB14988</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terbinafine</name>
        <accession>HMDB14995</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terbinafine</name>
        <accession>HMDB14995</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethanol</name>
        <accession>HMDB00108</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Almotriptan</name>
        <accession>HMDB15054</accession>
      </metabolite>
      <reference>
        <reference_text>Salva M, Jansat JM, Martinez-Tobed A, Palacios JM: Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.</reference_text>
        <pubmed_id>12642466</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tipranavir</name>
        <accession>HMDB15067</accession>
      </metabolite>
      <reference>
        <reference_text>Li F, Wang L, Guo GL, Ma X: Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38(5):871-8. Epub 2010 Jan 26.</reference_text>
        <pubmed_id>20103582</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tipranavir</name>
        <accession>HMDB15067</accession>
      </metabolite>
      <reference>
        <reference_text>Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD: A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42. Epub 2010 Feb 10.</reference_text>
        <pubmed_id>20147896</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aspirin</name>
        <accession>HMDB01879</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Felbamate</name>
        <accession>HMDB15084</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoniazid</name>
        <accession>HMDB15086</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telmisartan</name>
        <accession>HMDB15101</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desloratadine</name>
        <accession>HMDB15102</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ramelteon</name>
        <accession>HMDB15115</accession>
      </metabolite>
      <reference>
        <reference_text>Obach RS, Ryder TF: Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91. Epub 2010 May 17.</reference_text>
        <pubmed_id>20478852</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Formoterol</name>
        <accession>HMDB15118</accession>
      </metabolite>
      <reference>
        <reference_text>Somers GI, Lindsay N, Lowdon BM, Jones AE, Freathy C, Ho S, Woodrooffe AJ, Bayliss MK, Manchee GR: A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805. Epub 2007 Jul 12.</reference_text>
        <pubmed_id>17627976</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Formoterol</name>
        <accession>HMDB15118</accession>
      </metabolite>
      <reference>
        <reference_text>Zhang M, Fawcett JP, Kennedy JM, Shaw JP: Stereoselective glucuronidation of formoterol by human liver microsomes.  Br J Clin Pharmacol. 2000 Feb;49(2):152-7.</reference_text>
        <pubmed_id>10671910</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dopamine</name>
        <accession>HMDB00073</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tioconazole</name>
        <accession>HMDB15142</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Guanfacine</name>
        <accession>HMDB15153</accession>
      </metabolite>
      <reference>
        <reference_text>Clement B, Demesmaeker M: Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6.</reference_text>
        <pubmed_id>9396389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Guanfacine</name>
        <accession>HMDB15153</accession>
      </metabolite>
      <reference>
        <reference_text>Guillouzo A, Le Bigot JF, Guguen-Guillouzo C, Kiechel JR: Presence of phase I and phase II drug metabolizing enzymes in cultured human foetal hepatocytes. Biochem Pharmacol. 1982 Jul 15;31(14):2427-30.</reference_text>
        <pubmed_id>6751332</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Probenecid</name>
        <accession>HMDB15166</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Dealkylated tolterodine</name>
        <accession>HMDB13972</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Dealkylated tolterodine</name>
        <accession>HMDB13972</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>cis,trans-5'-Hydroxythalidomide</name>
        <accession>HMDB13870</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>cis,trans-5'-Hydroxythalidomide</name>
        <accession>HMDB13870</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Memantine</name>
        <accession>HMDB15177</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Praziquantel</name>
        <accession>HMDB15191</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amoxicillin</name>
        <accession>HMDB15193</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dimethyl sulfoxide</name>
        <accession>HMDB02151</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxyfluvastatin</name>
        <accession>HMDB14037</accession>
      </metabolite>
      <reference>
        <reference_text>Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.</reference_text>
        <pubmed_id>11523064</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rosuvastatin</name>
        <accession>HMDB15230</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pimozide</name>
        <accession>HMDB15232</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miconazole</name>
        <accession>HMDB15242</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>7-Hydroxygliclazide</name>
        <accession>HMDB14027</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>7-Hydroxygliclazide</name>
        <accession>HMDB14027</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolbutamide</name>
        <accession>HMDB15256</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolbutamide</name>
        <accession>HMDB15256</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolbutamide</name>
        <accession>HMDB15256</accession>
      </metabolite>
      <reference>
        <reference_text>Lasker JM, Wester MR, Aramsombatdee E, Raucy JL: Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys. 1998 May 1;353(1):16-28.</reference_text>
        <pubmed_id>9578596</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bicalutamide</name>
        <accession>HMDB15260</accession>
      </metabolite>
      <reference>
        <reference_text>Cockshott ID: Bicalutamide: clinical pharmacokinetics and metabolism.  Clin Pharmacokinet. 2004;43(13):855-78.</reference_text>
        <pubmed_id>15509184</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Proguanil</name>
        <accession>HMDB15263</accession>
      </metabolite>
      <reference>
        <reference_text>Lu AH, Shu Y, Huang SL, Wang W, Ou-Yang DS, Zhou HH: In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes. Acta Pharmacol Sin. 2000 Aug;21(8):747-52.</reference_text>
        <pubmed_id>11501186</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Proguanil</name>
        <accession>HMDB15263</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pioglitazone</name>
        <accession>HMDB15264</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80.</reference_text>
        <pubmed_id>12360109</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C: The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7.</reference_text>
        <pubmed_id>12180536</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cilostazol</name>
        <accession>HMDB15297</accession>
      </metabolite>
      <reference>
        <reference_text>Suri A, Forbes WP, Bramer SL: Effects of CYP3A inhibition on the metabolism of cilostazol.  Clin Pharmacokinet. 1999;37 Suppl 2:61-8.</reference_text>
        <pubmed_id>10702888</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Moclobemide</name>
        <accession>HMDB15302</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Podofilox</name>
        <accession>HMDB15310</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Dechloroethylifosfamide</name>
        <accession>HMDB13858</accession>
      </metabolite>
      <reference>
        <reference_text>Roy P, Yu LJ, Crespi CL, Waxman DJ: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.</reference_text>
        <pubmed_id>10348794</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Dechloroethylifosfamide</name>
        <accession>HMDB13858</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexfenfluramine</name>
        <accession>HMDB15322</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clarithromycin</name>
        <accession>HMDB15342</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saquinavir</name>
        <accession>HMDB15362</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexamethasone</name>
        <accession>HMDB15364</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gemfibrozil</name>
        <accession>HMDB15371</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomipramine</name>
        <accession>HMDB15372</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lapatinib</name>
        <accession>HMDB15388</accession>
      </metabolite>
      <reference>
        <reference_text>Medina PJ, Goodin S: Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008 Aug;30(8):1426-47.</reference_text>
        <pubmed_id>18803986</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lapatinib</name>
        <accession>HMDB15388</accession>
      </metabolite>
      <reference>
        <reference_text>van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors.  Cancer Treat Rev. 2009 Dec;35(8):692-706. Epub 2009 Sep 5.</reference_text>
        <pubmed_id>19733976</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Arformoterol</name>
        <accession>HMDB15399</accession>
      </metabolite>
      <reference>
        <reference_text>Somers GI, Lindsay N, Lowdon BM, Jones AE, Freathy C, Ho S, Woodrooffe AJ, Bayliss MK, Manchee GR: A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805. Epub 2007 Jul 12.</reference_text>
        <pubmed_id>17627976</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Arformoterol</name>
        <accession>HMDB15399</accession>
      </metabolite>
      <reference>
        <reference_text>Zhang M, Fawcett JP, Kennedy JM, Shaw JP: Stereoselective glucuronidation of formoterol by human liver microsomes.  Br J Clin Pharmacol. 2000 Feb;49(2):152-7.</reference_text>
        <pubmed_id>10671910</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lumiracoxib</name>
        <accession>HMDB15403</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lumiracoxib</name>
        <accession>HMDB15403</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fosphenytoin</name>
        <accession>HMDB15417</accession>
      </metabolite>
      <reference>
        <reference_text>Anderson GD: Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. Ther Drug Monit. 2008 Apr;30(2):173-80.</reference_text>
        <pubmed_id>18367977</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fosphenytoin</name>
        <accession>HMDB15417</accession>
      </metabolite>
      <reference>
        <reference_text>Hennessy S, Leonard CE, Freeman CP, Metlay JP, Chu X, Strom BL, Bilker WB: CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity.  J Clin Pharmacol. 2009 Dec;49(12):1483-7. Epub 2009 Jul 17.</reference_text>
        <pubmed_id>19617466</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fosphenytoin</name>
        <accession>HMDB15417</accession>
      </metabolite>
      <reference>
        <reference_text>Klotz U: The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 2007;46(4):271-9.</reference_text>
        <pubmed_id>17375979</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3'-Hydroxyhexobarbital</name>
        <accession>HMDB13940</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3'-Hydroxyhexobarbital</name>
        <accession>HMDB13940</accession>
      </metabolite>
      <reference>
        <reference_text>Adedoyin A, Prakash C, O'Shea D, Blair IA, Wilkinson GR: Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics. 1994 Feb;4(1):27-38.</reference_text>
        <pubmed_id>8004130</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3'-Hydroxyhexobarbital</name>
        <accession>HMDB13940</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3'-Hydroxyhexobarbital</name>
        <accession>HMDB13940</accession>
      </metabolite>
      <reference>
        <reference_text>Lewis DF, Modi S, Dickins M: Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.</reference_text>
        <pubmed_id>11996013</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Troleandomycin</name>
        <accession>HMDB15448</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acenocoumarol</name>
        <accession>HMDB15487</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylaminopyrine</name>
        <accession>HMDB13839</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylaminopyrine</name>
        <accession>HMDB13839</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Hydroxymethylantipyrine</name>
        <accession>HMDB13840</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Hydroxymethylantipyrine</name>
        <accession>HMDB13840</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromazepam</name>
        <accession>HMDB15511</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clotiazepam</name>
        <accession>HMDB15512</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quazepam</name>
        <accession>HMDB15528</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lopinavir</name>
        <accession>HMDB15539</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pipotiazine</name>
        <accession>HMDB15558</accession>
      </metabolite>
      <reference>
        <reference_text>Wojcikowski J, Boksa J, Daniel WA: Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9. Epub 2010 Jul 6.</reference_text>
        <pubmed_id>20615392</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxymethyletoricoxib</name>
        <accession>HMDB13997</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bifonazole</name>
        <accession>HMDB15583</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trabectedin</name>
        <accession>HMDB15609</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trabectedin</name>
        <accession>HMDB15609</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methsuximide</name>
        <accession>HMDB15611</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitaxentan</name>
        <accession>HMDB15629</accession>
      </metabolite>
      <reference>
        <reference_text>Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J: Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest. 2002 Jun;121(6):1860-8.</reference_text>
        <pubmed_id>12065350</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Artemether</name>
        <accession>HMDB15643</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Artemether</name>
        <accession>HMDB15643</accession>
      </metabolite>
      <reference>
        <reference_text>Elsherbiny DA, Asimus SA, Karlsson MO, Ashton M, Simonsson US: A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn. 2008 Apr;35(2):203-17. Epub 2008 Mar 19.</reference_text>
        <pubmed_id>18350255</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nilvadipine</name>
        <accession>HMDB15657</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fospropofol</name>
        <accession>HMDB15661</accession>
      </metabolite>
      <reference>
        <reference_text>Guitton J, Buronfosse T, Desage M, Flinois JP, Perdrix JP, Brazier JL, Beaune P: Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.</reference_text>
        <pubmed_id>9771309</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fosaprepitant</name>
        <accession>HMDB15662</accession>
      </metabolite>
      <reference>
        <reference_text>Navari RM: Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2008 Nov;8(11):1733-42.</reference_text>
        <pubmed_id>18983233</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
